Cord blood: spotlight on the processing step
|
|
- Rafe Isaac Wheeler
- 8 years ago
- Views:
Transcription
1 RESEARCH HIGHLIGHT Cord blood: spotlight on the processing step Nobuhiko Sato 1, Cornelia Fricke 2 1 Kaneka Corporation, Medical Devices Division, Nakanoshima, Kita-ku, Osaka , Japan 2 Kaneka Pharma Europe N.V. - German Branch, Frankfurter Straße 80-82, Eschborn, Germany Correspondence: Cornelia Fricke cornelia.fricke@kaneka.de Received: March 29, 2016 Published online: May 09, 2016 Cord blood (CB) can be stored processed or un-processed. The advantage of applying a processing step to the cord blood units (CBUs) for cord blood banks (CBBs) is that the volume can be reduced by depletion of plasma and sometimes also by reduction of red blood cell (RBC) number. This decreases the associated costs for storage. Another advantage is the reduction of the quantity of cryopreservation solution in the final product. As the RBCs tend to burst during the freezing and thawing step the decrease in RBC numbers reduces the possibly harmful cellular debris and free hemoglobin released by burst RBCs into the CBUs. However processing can potentially cause also a loss of the wanted cells, like the stem cell compartment or cause stress to these cells. Thus, the optimal processing system reduces volume and RBCs while at the same time leaving the wanted cells like the stem cell compartment with its hematopoietic as well as non-hematopoietic stem cells unaffected. Hematopoietic stem cells are mainly used as a source for transplants to reconstitute the blood forming cells and immune system while non-hematopoietic stem cells can support the hematopoietic stem cells in the transplant setting but are potentially useful also for other regenerative medicine or immune modulatory purposes. Many CBBs today use a processing step instead of storing the CB un-processed just by the addition of cryopreservation solution. Different processing systems exist which often employ a centrifugation step for processing of the CBUs. In addition, we described recently a manual system, CellEffic CB, which employs a filtration step eliminating the need for centrifugation and thus any machines and its associated costs. We will highlight here recent development in the cord blood industry and how the new filtration system can contribute to this industry. Keywords: Cord Blood; Cord Blood Banking; Processing; Filtration To cite this article: Nobuhiko Sato, et al. Cord blood: spotlight on the processing step. Stem Cell Transl Investig 2016; 3: e1284. doi: /scti Copyright: 2016 The Authors. Licensed under a Creative Commons Attribution 4.0 International License which allows users including authors of articles to copy and redistribute the material in any medium or format, in addition to remix, transform, and build upon the material for any purpose, even commercially, as long as the author and original source are properly cited or credited. Starting in the early 90s, cord blood banking has since then increased in terms of number of CBBs and of CBUs stored worldwide. An estimated ~4.73 million CBUs are stored in public as well as private banks, with more CBUs stored in private banks [1]. Public banks store the CBUs for principally allogeneic use applied in unrelated, but sometimes also related, patients as a cord blood transplant (CBT) for hematopoietic reconstitution while private CBBs store the CBUs for a yearly fee for the purpose of using the CB autologous or within this particular family. Also, some mixed forms of banking exist. As of 2015, more CBUs from public banks have been applied clinically than from private banks [1]. Obtaining the CB from the cord, which in the past was treated as medical waste, after birth of the child is without harm for the infant and mother. However, it has to be noted that delayed clamping is in general recommended by Page 1 of 6
2 the WHO in respect to infant and maternal health and nutrition outcomes [2]. From the place of delivery, where the CB is collected by specifically trained staff, the CB is transported to the CBBs at optimally a controlled temperature - in order to avoid extreme temperature exposures - for further processing and storage until the CB is finally released for therapeutic use when needed. Hematopoietic stem cell transplants of CBUs have been reported primarily in the allogeneic setting, among them in the related (family) as well as in the unrelated setting [3]. More CBT have been performed from 1988 to 2014 in the unrelated setting, or 92%, than in the related setting, 826 or 8%, as reported by Eurocord in 2015 without CBTs performed in the United States [4]. Within the family, hematopoietic stem cell transplantation with CB has been utilized in malignant as well as non-malignant disease [5] like in leukemia [6] or hemoglobinopathies [7] and in the unrelated setting in, among others, leukemias, lymphomas, [see for hemoglobinopathies, and myelodysplastic syndromes example 8-13]. However, the majority of unrelated CBT is rather applied in malignant diseases (5795 or 79%) than in non-malignant diseases (1530 or 21%) as published by Eurocord in 2015 [4]. A list of number of CBTs in particular diseases, where the CB has been provided by the New York Blood Center, is available by the New York Blood Center s National Cord Blood Program [14]. In terms of other regenerative medicine and immune modulation purposes, CB and CB-derived cells are under intense preclinical investigation for the use in stroke, limb ischemia and myocardial regeneration [15 and references herein], type I diabetes [16, 17], and foot disease in type II diabetes [18]. In addition, also some clinical data exists today, for example a clinical trial using allogeneic cord blood in combination with recombinant human erythropoietin, which by itself has neurotrophic effects, has shown improvement in motor and cognitive dysfunction in children with cerebral palsy [19]. Furthermore, a report of application of autologous CB in conjunction with Granulocyte Colony Stimulating Factor (G-CSF) in two toddlers with cerebral palsy was found to be safe, feasible and to display some functional improvement [20]. We will subsequently focus on recent findings of autologous CB and its cells, which have been banked or not, in regenerative medicine for non-hematopoietic applications. Feasibility [21-23] and safety [22, 23] with indication of potential benefits [23] of autologous cord blood cells has been shown in brain disease/disorder. Also a report on the application of autologous CB in a case of cerebral palsy was published and the observed functional neurologic regeneration in this case [24] was associated with the fact that mononuclear cells (MNCs) derived from human CB can migrate to lesioned region in the brain in a rat model of perinatal cerebral hypoxia-ischemia [25, 26]. Another preclinical report testing human CB in a rabbit model of cerebral palsy suggests that the observed beneficial effects might be due to paracrine signaling rather than cellular integration [27]. These different findings might be explained by the different delivery routes, intraperitoneal versus intravenous injection, of the cells in these preclinical experiments. In 2015, a larger clinical trial using autologous CB in children with cerebral palsy found a strong correlation between increase in white matter connectivity and functional improvement [28]. However, the contribution of the treatment with CB to the functional improvement was not analyzed in this work. Another case report of CB-derived cells in an autologous setting, namely in regenerative therapy for left heart syndrome, mentions a progressive improvement in the right ventricular ejection fraction [29]. Also in this case the contribution of the cell therapy to the observed beneficial effect has yet to be determined. Taken together it needs to be noted that there is mainly preclinical data available and only little published clinical data for efficacy of autologous CB and its cells in regenerative medicine, while it appears feasible and safe. The community will watch closely for further development in this area. The CB stored in the CBB, until applied as either for CBT of hematopoietic stem cells or for regenerative medicine / immune modulation purpose, needs to go through a series of steps, each one potentially causing stress to the cells. In brief, the CB is first collected, then it is transported to the CBB. Third, it is processed or stored un-processed. Addition of cryopreservation solution is the forth step. Then, CB is stored in the vapor phase of liquid nitrogen, after having been cooled down by a controlled rate freezer, for an extended time until it is needed. Next, the CB is transported to and received by, still frozen below -150 C, the transplant center [30]. Last but not least, the CB is thawed which might include a washing step and applied. At different steps the CB is tested for a series of markers and potency. While the cord blood cells can potentially be compromised at all of these steps, the remaining part of our research highlight will focus on the processing step of the CBU. Different processing systems exist today. Many of them are based on centrifugal force and employ one kind of sedimentation agent or another in order to reduce RBCs efficiently. We have shown for a new kind of processing system, which is based on a filter and doesn t require centrifugation, that it works equally well with a sedimentation agent [hydroxyethyl starch (HES) solution] as well as without any sedimentation agent just by the use of physiological saline solution in terms of reduction of RBCs and recovery post-processing of total nucleated cells (TNCs), MNCs as well as CD34+ cells [31]. This is noteworthy as another processing system has been reported to have Page 2 of 6
3 Figure 1. Shown are some characteristics of CB after being processed in an ideal case scenario. comparably lower RBC reduction without HES [31, 32] than a third report which shows for the same processing system a higher RBC reduction when used with HES [33]. As the filter-based device for processing of CBUs, CellEffic CB, is new on the market it was important for us to show that reduction of RBC numbers post-processing was not due to damage of RBCs by the whole processing procedure with the device. This was done by measuring plasma-free hemoglobin levels (N. Sato, unpublished data). Impact of higher number of RBCs on CBUs has to be determined, however more cellular debris and free hemoglobin from burst RBCs will be released into the CBU after freezing and thawing. In bone marrow transplant setting it was suggested to minimize the hemolysate content of cryopreserved bone marrow as this was associated with acute renal failure [34]. In the extreme case of not removing RBCs, the use of RBC-replete, unwashed CBUs has been associated with severe or even life-threatening infusion-related adverse events [35]. Thus, a RBC-replete CBU should ideally be washed, however RBC-replete CBUs have been reported to be more complicated to wash as the cellular debris and free haemoglobin can interfere with the demarcation of the interface between mononuclear cells and the supernatant, and can contribute to viscosity and clumping. [35]. Based on this we conclude that RBCs should be removed to a low level of contaminating cells before freezing and thawing by processing of the CBU. Furthermore, reduction of the volume of the CBU stored by processing the CBU leads to a reduction of the volume of cryopreservation solution in the final product [36]. Additionally, processing the CBU usually also removes the plasma and this will result in even smaller CBUs to be stored and thus reduces the storage costs. These latter ones consist not only of liquid nitrogen consumption but also of storage space including the liquid nitrogen tanks needed as well as the space for the liquid nitrogen tanks, and electricity. Since early on in the history of cord blood banking, the processing of CBUs was seen as a solution to reduce the storage space needed for the frozen CB samples [37]. However, care has to be taken not to remove too much of the wanted cells during processing, like the cells which constitute the stem cell compartment. Taken together, cord blood processing is a trade-off between reducing RBCs and plasma while keeping other cells unaffected and highly recovered [36]. Figure 1 shows the effect of cord blood processing in an ideal case scenario. The new filter-based device, CellEffic CB, which we described recently [31], can reduce the volume of the CBU up to 21mL minimum volume (without cryopreservation solution), which is within the range of volume of processed CB aimed often by CBBs to store as of today. Importantly, at the same time different stage hematopoietic and non-hematopoietic stem cells, which are useful for hematopoietic reconstitution and potentially for other regenerative medicine / immune modulatory purposes, can be recovered with CellEffic CB [31]. To our knowledge, for most clinicians today, the TNC count in the processed CBU is the most influencing factor Page 3 of 6
4 next to human leukocyte antigen (HLA) matching - to decide which of the CBUs to use as CBT in the unrelated setting. This is consistent with a report on how unrelated CBUs for CBTs are selected at the transplant service at the Memorial [38]. Sloan-Kettering Cancer Center in New York Additionally, a study by Bart et al. has found that units in US and Switzerland selected for transplants are rather the ones with higher TNC counts [39]. However, other factors despite TNC count, like bank of origin, infectious disease markers, sterility, and hemoglobinopathy screening, have been reported to play a role in selecting the CBU used in the transplant setting [38]. We especially want to point out the colony-forming unit (CFU) ability of the CBU after thawing of the stored CB. A single-center study of 435 unrelated CBTs has identified total CFUs post-thaw as strong predictor of neutrophil and platelet engraftment [40]. We presented data that the filter-based device, CellEffic CB, is next to good TNC viability post-processing as well as post-thaw - able to recover CFUs to an extremely high level even after freezing and thawing [31]. We conclude that this points to a gentle processing by the filter, which consists of nonchemical coated and non-woven polyester fabric [41], as the cord blood processing step is driven by gravity only without applying centrifugal force to the cells. As CFU assay requires two weeks to be performed, a more rapid CB potency assay which determines aldehyde dehydrogenase bright (ALDH br ) content found to be correlated with CFU content, might be useful after further validation as an alternative to CFU assay post-thaw for prediction of the ability of the CBU to engraft [42]. A recently reported decrease in CBT in absolute numbers [43] might be an indicator for the need to store more high quality CBU based on the potency of the CBU post-thaw. To date, multiple cord blood processing devices and methods exist which have been analyzed in terms of cell [31, 33, 36, 44, recovery and depletion in different compositions 45]. Some CBBs prefer automated systems, which can be explained by certain advantages associated with automation [36, 44], but to our knowledge this is rarely based on systematical analysis for contribution of recovered cells and influence of contaminating RBCs retrieved by different processing methods in the clinics. Also manual methods are used today and we believe that clinical data and / or data from animal models for the different processing methods need to be compared and attributed to differences in cell composition and potency post-process and, in the cases where the CB is stored before usage, post-thaw in order to decide on the optimal processing system. Identifying the optimal processing system might also help to overcome some of the limitations of CBT, like the reported poor immune cell reconstitution and delayed engraftment [3]. Conflicting interests Kaneka Corporation is manufacturer of CellEffic CB and Kaneka Pharma Europe N.V. is the European authorized representative and distributor for CellEffic CB. The work has been financed by Kaneka Corporation. Acknowledgements The authors wish to thank all members of CTI-Biotech who conducted the research work with CellEffic CB and comparison to an automated system, which was funded by Kaneka Corporation. Author contributions NS designed, conducted the work and analyzed the results. NS, CF reviewed and interpreted the data. CF wrote the manuscript. All authors read and approved the final manuscript. Abbreviation ALDH br : aldehyde dehydrogenase bright; CB: cord blood; CBB: cord blood bank; CBT: cord blood transplant; CBU: cord blood unit; CFU: colony-forming unit; G-CSF: Granulocyte Colony Stimulating Factor; HES: hydroxyethyl starch; HLA: human leukocyte antigen; MNC: mononuclear cell; RBC: red blood cell; TNC: total nucleated cell. References 1. Ballen KK, Verter F, Kurtzberg J. Umbilical cord blood donation: public or private? Bone Marrow Transplant 2015; 50: WHO [ 3. Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood 2013; 122: Eurocord [ 5. Wagner JE, Kernan NA, Steinbuch M, Broxmeyer HE, Gluckman E. Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease. Lancet. 1995; 346: Heath JA, Campbell M, Tiedemann K, Downie PA. Successful matched sibling cord blood transplant for ALL in a child with constitutional mismatch repair deficiency syndrome. Bone Marrow Transplant 2016; doi: /bmt Locatelli F, Kabbara N, Ruggeri A, Ghavamzadeh A, Roberts I, Li CK et al. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood 2013; 122: Ballen KK, Lazarus H. Cord blood transplant for acute myeloid leukaemia. Br J Haematol 2016; doi: /bjh Bradstock KF, Hertzberg MS, Kerridge IH, Svennilson J, Page 4 of 6
5 McGurgan M, Huang G et al. Unrelated umbilical cord blood transplantation for adults with haematological malignancies: results from a single Australian centre. Intern Med J 2006; 36: Sebrango A, Vicuña I, de Laiglesia A, Millán I, Bautista G, Martín-Donaire T et al. Haematopoietic transplants combining a single unrelated cord blood unit and mobilized haematopoietic stem cells from an adult HLA-mismatched third party donor. Comparable results to transplants from HLA-identical related donors in adults with acute leukaemia and myelodysplastic syndromes. Best Pract Res Clin Haematol 2010; 23: Rodrigues CA, Rocha V, Dreger P, Brunstein C, Sengeloev H, Finke J et al. Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after reduced-intensity conditioning regimen: similar outcomes with umbilical cord blood and unrelated donor peripheral blood. Haematologica 2014; 99: Mazur M, Kurtzberg J, Halperin E, Ciocci G, Szabolcs P. Transplantation of a child with sickle cell anemia with an unrelated cord blood unit after reduced intensity conditioning. J Pediatr Hematol Oncol 2006; 28: Marks DI, Woo KA, Zhong X, Appelbaum FR, Bachanova V, Barker JN et al. Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donors. Haematologica 2014; 99: The National Cord Blood Program [ eases.pdf, 2016] 15. Riordan NH, Chan K, Marleau AM, Ichim TE. Cord blood in regenerative medicine: do we need immune suppression? J Transl Med 2007; 5: He B, Li X, Yu H, Zhou Z. Therapeutic potential of umbilical cord blood cells for type 1 diabetes mellitus. J Diabetes 2015; 7: Theil A, Wilhelm C, Guhr E, Reinhardt J, Bonifacio E. The relative merits of cord blood as a cell source for autologous T regulatory cell therapy in type 1 diabetes. Horm Metab Res 2015; 47: Li XY, Zheng ZH, Li XY, Guo J, Zhang Y, Li H et al. Treatment of foot disease in patients with type 2 diabetes mellitus using human umbilical cord blood mesenchymal stem cells: response and correction of immunological anomalies. Curr Pharm Des 2013; 19: Min K, Song J, Kang JY, Ko J, Ryu JS, Kang MS et al. Umbilical cord blood therapy potentiated with erythropoietin for children with cerebral palsy: a double-blind, randomized, placebo-controlled trial. Stem Cells 2013; 31: Papadopoulos KI, Low SS, Aw TC, Chantarojansiri T. Safety and feasibility of autologous umbilical cord blood transfusion in 2 toddlers with cerebral palsy and the role of low dose granulocyte-colony stimulating factor injections. Restor Neurol Neurosci 2011; 29: Cotten CM, Murtha AP, Goldberg RN, Grotegut CA, Smith PB, Goldstein RF et al. Feasibility of autologous cord blood cells for infants with hypoxic-ischemic encephalopathy. J Pediatr 2014; 164: Sun JM, Grant GA, McLaughlin C, Allison J, Fitzgerald A, Waters-Pick B et al. Repeated autologous umbilical cord blood infusions are feasible and had no acute safety issues in young babies with congenital hydrocephalus. Pediatr Res 2015; 78: Lee YH, Choi KV, Moon JH, Jun HJ, Kang HR, Oh SI et al. Safety and feasibility of countering neurological impairment by intravenous administration of autologous cord blood in cerebral palsy. J Transl Med 2012; 10: Jensen A, Hamelmann E. First autologous cell therapy of cerebral palsy caused by hypoxic-ischemic brain damage in a child after cardiac arrest-individual treatment with cord blood. Case Rep Transplant 2013; 2013: doi: /2013/ Jensen A, Vaihinger HM, Meier C. Perinatal brain damage from neuroprotection to neuroregeneration using cord blood stem cells. Med Klin (Munich) 2003; 98: Meier C, Middelanis J, Wasielewski B, Neuhoff S, Roth-Haerer A, Gantert M et al. Spastic paresis after perinatal brain damage in rats is reduced by human cord blood mononuclear cells. Pediatr Res 2006; 59: Drobyshevsky A, Cotten CM, Shi Z, Luo K, Jiang R, Derrick M et al. Human Umbilical Cord Blood Cells Ameliorate Motor Deficits in Rabbits in a Cerebral Palsy Model. Dev Neurosci 2015; 37: Englander ZA, Sun J, Case L, Mikati MA, Kurtzberg J, Song AW. Brain structural connectivity increases concurrent with functional improvement: evidence from diffusion tensor MRI in children with cerebral palsy during therapy. Neuroimage Clin 2015; 9: Burkhart HM, Qureshi MY, Peral SC, O'Leary PW, Olson TM, Cetta F et al. Regenerative therapy for hypoplastic left heart syndrome: first report of intraoperative intramyocardial injection of autologous umbilical-cord blood-derived cells. J Thorac Cardiovasc Surg 2015; 149:e Rubinstein P. Cord blood banking for clinical transplantation. Bone Marrow Transplant 2009; 44: Sato N, Fricke C, McGuckin C, Forraz N, Degoul O, Atzeni G et al. Cord blood processing by a novel filtration system. Cell Prolif 2015; 48: Zingsem J, Strasser E, Weisbach V, Zimmermann R, Ringwald J, Goecke T et al. Cord blood processing with an automated and functionally closed system. Transfusion 2003; 43: Solves P, Planelles D, Mirabet V, Blanquer A, Carbonell-Uberos F. Qualitative and quantitative cell recovery in umbilical cord blood processed by two automated devices in routine cord blood banking: a comparative study. Blood Transfus 2013; 11: Smith DM, Weisenburger DD, Bierman P, Kessinger A, Vaughan WP, Armitage JO. Acute renal failure associated with autologous bone marrow transplantation. Bone Marrow Transplant 1987; 2: Barker JN, Scaradavou A. Response: the controversy of red blood cell-replete cord blood units. Blood 2011; 118: Solves P, Mirabet V, Roig R. Volume reduction in routine cord blood banking. Curr Stem Cell Res Ther 2010; 5: Sousa T, de Sousa ME, Godinho MI, Mendes C, Carvalhais A, Barbosa IL. Umbilical cord blood processing: volume reduction and recovery of CD34+ cells. Bone Marrow Transplant 1997; Page 5 of 6
6 19: Barker JN, Byam C, Scaradavou A. How I treat: the selection and acquisition of unrelated cord blood grafts. Blood 2011; 117: Bart T, Boo M, Balabanova S, Fischer Y, Nicoloso G, Foeken L et al. Impact of selection of cord blood units from the United States and swiss registries on the cost of banking operations. Transfus Med Hemother 2013; 40: Page KM, Zhang L, Mendizabal A, Wease S, Carter S, Gentry T et al. Total colony-forming units are a strong, independent predictor of neutrophil and platelet engraftment after unrelated umbilical cord blood transplantation: a single-center analysis of 435 cord blood transplants. Biol Blood Marrow Transplant 2011; 17: Shima T, Forraz N, Sato N, Yamauchi T, Iwasaki H, Takenaka K et al. A novel filtration method for cord blood processing using a polyester fabric filter. Int J Lab Hematol 2013; 35: Shoulars KW, Noldner P, Troy JD, Cheatham L, Parrish A, Page K et al. Development and validation of a rapid, aldehyde dehydrogenase bright-based, cord blood potency assay. Blood 2016; doi: /blood Passweg JR, Baldomero H, Bader P, Bonini C, Cesaro S, Dreger P et al. Hematopoietic stem cell transplantation in Europe 2014: more than transplants annually. Bone Marrow Transplant 2016; doi: /bmt Solves P, Mirabet V, Blanquer A, Degado-Rosas F, Planelles D, Andrade M et al. A new automatic device for routine cord blood banking: critical analysis of different volume reduction methodologies. Cytotherapy 2009; 11: Basford C, Forraz N, Habibollah S, Hanger K, McGuckin C. The cord blood separation league table: a comparison of the major clinical grade harvesting techniques for cord blood stem cells. Int J Stem Cells 2010;3: Page 6 of 6
Public Cord Blood Banking at the National Cord Blood Program (NCBP)
Public Cord Blood Banking at the National Cord Blood Program (NCBP) A. Scaradavou, MD Medical Director, National Cord Blood Program, New York Blood Center Associate Attending, Pediatric BMT Memorial Sloan-Kettering
More informationNewborn Stem Cells from Cord Blood and the Brain: Repairing Injury and Improving Function
BACKROUNDER: Newborn Stem Cells from Cord Blood and the Brain: Repairing Injury and Improving Function Introduction WITH ONGOING DEVELOPMENTS IN RESEARCH, it is estimated that 1 in every 3 people may benefit
More informationUMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE
UMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE HIND AL HUMAIDAN, MD,FRCPA Director, Blood Bank (Donor & Transfusion Services) and Stem Cell Cord Blood Bank Consultant Hematopathologist INTRODUCTION
More informationVita 34 Parents Guide to umbilical Cord Blood Banking. secure first-class innovative
Vita 34 Parents Guide to umbilical Cord Blood Banking secure first-class innovative Contents INTRODUCTION 3 THERAPEUTIC USES OF STEM CELLS 4 STEM CELLS IN CANCER TREATMENT STEM CELLS IN THE TREATMENT OF
More informationProcessing & Utilization of Cord Blood for Transplant
Processing & Utilization of Cord Blood for Transplant 2010-Jan Jan-15 Nicole L. Prokopishyn, PhD HPC Processing Laboratory Director Calgary Laboratory Services Overview Cord Blood Processing Pre-Freeze
More informationSibling Donor Cord Blood Transplantation for Thalassemia Major: Experience of the Sibling Donor Cord Blood Program
Sibling Donor Cord Blood Transplantation for Thalassemia Major: Experience of the Sibling Donor Cord Blood Program MARK C. WALTERS, LYNN QUIROLO, ELIZABETH T. TRACHTENBERG, SANDIE EDWARDS, LISA HALE, JOANNA
More informationIn contrast to the very high transplant-related
Cord Blood: an Alternative Stem Cell Source or a New Standard? Juliet N. BARKER Memorial Sloan-Kettering Cancer Center, NY, ABD In contrast to the very high transplant-related mortality (TRM) associated
More informationUMBILICAL CORD BLOOD COLLECTION
UMBILICAL CORD BLOOD COLLECTION by Frances Verter, PhD Founder & Director, Parent's Guide to Cord Blood Foundation info@parentsguidecordblood.org and Kim Petrella, RN Department of Obstetrics and Gynecology
More informationDEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT
www.narayanahealth.org DEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT About Narayana Health City Narayana Health, one of India's largest and the world's most economical healthcare service providers
More informationA Cure for Sickle Cell Anemia and Thalassemia
IV Simpósio Internacional de Hemoglobinopatias A Cure for Sickle Cell Anemia and Thalassemia Bertram Lubin, MD and Mark Walters, MD 4 September 2007 Topics to be covered Cord blood: Importance and biology
More informationPreparation of cord blood for infusion: bedside thaw, dilute and wash, or somewhere in between
Preparation of cord blood for infusion: bedside thaw, dilute and wash, or somewhere in between Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program ISCT 2012 Disclosures: none The problem:
More informationStem cells from Cord Blood: Myths, reality and potential. Elisabeth Semple, PhD Scientific Director Cells for Life Cord Blood Institute
Stem cells from Cord Blood: Myths, reality and potential Elisabeth Semple, PhD Scientific Director Cells for Life Cord Blood Institute Learning objectives Understand the current usage of stem cells from
More informationFetal Maternal Immunity and Antileukemia Activity in Cord Blood Transplant. Recipients
Fetal Maternal Immunity and Antileukemia Activity in Cord Blood Transplant Recipients Filippo Milano, 1 J. Lee Nelson, 1, 2 Colleen Delaney 1,3 1 Clinical Research Division, Fred Hutchinson Cancer Research
More informationSTEM CELLS FROM THE UMBLICAL CORD BLOOD AND UMBLICAL CORD TISSUE
STEM CELLS FROM THE UMBLICAL CORD BLOOD AND UMBLICAL CORD TISSUE What are Stem Cells? Stem cells are the basic building blocks of all the cells, tissues and organs in the human body. The role of the stem
More informationHematopoiesis i starts from. HPC differentiates t to sequentially more mature. HPC circulate in very low
Upstate Cord Blood Bank Hematopoietic Progenitor Cells Hematopoiesis i starts from self renewing HPC HPC differentiates t to sequentially more mature blood cells HPC circulate in very low numbers in adults
More informationHow To Transplant Cord Blood
MP 7.01.38 Placental/Umbilical Cord Blood as a Source of Stem Cells Medical Policy Section Surgery Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013
More informationCord Blood: that other stem cell source. Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program
Cord Blood: that other stem cell source Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program CBMTG April 2012 The problem: In order to perform a BMT from one person to another one needs
More informationAutomated Cord Blood Processing:
TM Automated Cord Blood Processing: A Follow-up to the Pilar Solves Study Comparing the AXP vs the Sepax Cord Blood Processing Systems CHRISTY KIM, PETRA CRAVENS, MINDY WILKE-DOUGLAS AND MITCHEL SIVILOTTI
More informationSelecting an appropriately matched donor for hematopoietic
Transplant Outcomes in Acute Leukemia (I) Mary Eapen a and John E. Wagner b Umbilical cord blood (UCB) has gradually emerged over the last decade as an alternative source of hematopoietic cells for transplantation
More informationSaving Your Baby s Cord Blood
Saving Your Baby s Cord Blood An Important Pregnancy Decision 1-888-CORD BLOOD HEALTHY FUTURES ARE Born at CBR For every parent who wishes they could do more to protect their family s health, there s Cord
More informationCIGNA HEALTHCARE COVERAGE POSITION
CIGNA HEALTHCARE COVERAGE POSITION Subject Umbilical Cord Blood Banking Table of Contents Coverage Position... 1 General Background... 1 Coding/Billing Information... 3 References... 3 Revised Date...
More informationUmbilical Cord Blood Transplantation
Umbilical Cord Blood Transplantation V Rocha MD, PhD Hopital Saint Louis, Paris University 7 CIBMTR Milwaukee Umbilical Cord blood transplantation Background History Clinical results in children and adults
More informationUMBILICAL CORD BLOOD BANKING A guide for parents
UMBILICAL CORD BLOOD BANKING A guide for parents 2 nd EDITION INTRODUCTION The cells contained in the umbilical cord blood have therapeutic value for the treatment of blood disorders and immune diseases.
More informationDiscover the Possibilities Born With Your Baby
Discover the Possibilities Born With Your Baby Your Simple Guide to Saving Cord Blood The Power and Promise The lifesaving power of cord blood and regenerative healing potential of cord blood and cord
More informationStem Cell Background Paper
Stem Cell Background Paper Introduction...2 Stem Cell Basics...3 Stem Cell Process Flow...9 Comparison of Blood, Stem Cells, Tissues and Organs Processes...10 Responsibilities for the Blood, Stem Cells,
More informationUMBILICAL CORD BLOOD STATISTICS
UMBILICAL CORD BLOOD STATISTICS INTRODUCTION Stem cells are the next frontier in medicine. Stem cells are thought to have great therapeutic and biotechnological potential. This will not only to replace
More informationBeyond Cell Dose: Selection of the Optimal Umbilical Cord Blood Unit. Karen Ballen, MD Massachusetts General Hospital June, 2012
Beyond Cell Dose: Selection of the Optimal Umbilical Cord Blood Unit Karen Ballen, MD Massachusetts General Hospital June, 2012 OUTLINE Cell Dose HLA Typing HLA C and KIR HLA Antibodies ABO and Racial/Ethnic
More informationIt s not something you want to think about, but it s something you want to prepare for.
It s not something you want to think about, but it s something you want to prepare for. StemCyte cord blood banking offers your family a new lifesaving treatment alternative Why Bank Take the once-in-alifetime
More information4. All cord blood banks should be subject to the same standards, regulations and accreditation requirements.
WMDA Policy Statement on the Utility of Autologous or Family Cord Blood Unit Storage The WMDA Board adopted this policy on 25 th of May 2006. Policy updated _April 2011 The Cord Blood Working Group and
More informationStem Cell Banking. Umbilical Cord. The Leading Cell Bank www.stemology.co.uk. Protect your family s future
Protect your family s future The Leading Cell Bank www.stemology.co.uk Stem Cell Banking Umbilical Cord For women in their 1st, 2nd or 3rd Trimester of Pregnancy Introduction to Stemology Imagine you
More informationPT CordLife Indonesia Premium Cordblood Bank. PT CordLife Indonesia Premium Cordblood Bank
Cordblood Stem Cells and The Role of Cordblood Bank in Supporting Stem Cells Research Presentation Overview Company profile Haematopoietic stem cells in cordblood What we can do to help 1 2 PT CordLife
More informationPlacental and Umbilical Cord Blood as a Source of Stem Cells
Placental and Umbilical Cord Blood as a Source of Stem Cells Policy Number: 7.01.50 Last Review: 12/2015 Origination: 12/2001 Next Review: 12/2016 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationRecommendations to Transplant Centres Performing Cord Blood Transplants. Why Choosing the Right Thaw Method Could Save a Patient s Life
Recommendations to Transplant Centres Performing Cord Blood Transplants Vicki Antonenas Why Choosing the Right Thaw Method Could Save a Patient s Life Lynn O Donnell (USA) 1 The process of receiving, testing
More informationThe Facts about Cord Blood
The Facts about Cord Blood Dear Future Mom and/or Dad, All of us at CorCell would like to give you a big CONGRATULATIONS on your new baby! Now that you are expecting, you have probably heard about saving
More informationCord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape
GENReports: Market & Tech Analysis Cord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape > Enal Razvi, Ph.D. Biotechnology Analyst, Managing Director SELECTBIO US enal@selectbio.us
More informationSection: Transplant Last Reviewed Date: January 2015. Policy No: 45.16 Effective Date: April 1, 2015
Medical Policy Manual Topic: Placental and Umbilical Cord Blood as a Source of Stem Cells Date of Origin: December 2009 Section: Transplant Last Reviewed Date: January 2015 Policy No: 45.16 Effective Date:
More informationPr Eliane Gluckman, MD, FRCP, Disclosure of Interest: Nothing to Disclose
Pr Eliane Gluckman, MD, FRCP, Hospital Saint Louis, University Paris- Diderot, France Should Haplo-identical transplantation be preferred to cord blood in patients without a matched donor? Disclosure of
More information5. All cord blood banks should be subject to the same standards, regulations and accreditation requirements.
WMDA Policy Statement for the Utility of Autologous or Family Cord Blood Unit Storage (This policy statement has been approved and adopted by the WMDA board on the 25 th of May 2006) The Cord Blood Registries
More informationNot All Stem Cells are the Same
Cord Blood Banking and Transplantation Jennifer Willert, M.D. Hematology/Oncology Blood and Marrow Transplant Rady Children s Hospital San Diego Clinical Professor UCSD Not All Stem Cells are the Same
More informationCord Blood: Thawing & Infusion Practical Methods
Cord Blood: Thawing & Infusion Practical Methods Donna M Regan, MT(ASCP)SBB St. Louis Cord Blood Bank @ SSM Cardinal Glennon Children s s Medical Center Objectives Present variety of product configurations
More informationCPT Codes for Bone Marrow Transplant January 2015 James L. Gajewski, MD
The blood and marrow transplant field has 15 dedicated CPT codes. These CPT codes can be categorized into three groups: 1. Collection Codes 2. Cell Processing Codes 3. Cell Infusion Codes Collection Codes
More informationBone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation: Questions and Answers. Key Points
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Bone Marrow Transplantation
More informationThe Power & Potential of Cord Blood
The Power & Potential of Cord Blood Donna Regan, MT(ASCP)SBB, Director St. Louis Cord Blood Bank & Cellular Therapy Laboratory SSM Cardinal Glennon Children s Medical Center April 30, 2014 Objectives Since
More informationPlacental and Umbilical Cord Blood as a Source of Stem Cells
Placental and Umbilical Cord Blood as a Source of Stem Cells Policy Number: 7.01.50 Last Review: 12/2013 Origination: 12/2001 Next Review: 12/2014 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationStem Cell Transplantation
Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance
More informationCord Blood Stem Cell Transplantation
LEUKEMIA LYMPHOMA MYELOMA FACTS Cord Blood Stem Cell Transplantation No. 2 in a series providing the latest information on blood cancers Highlights Umbilical cord blood, like bone marrow and peripheral
More informationA Public Cord Blood Bank for South Africa? i
No. 42/2007 A Public Cord Blood Bank for South Africa? i By Dr Robert Crookes MBChB (Wits), Dip. Internal Medicine (American Board of Internal Medicine, USA) Transfusion Medicine Consultant. South African
More informationPublic Cord Blood Tissue Bank Committee on Health Care Services and Representative Peaden
HOUSE OF REPRESENTATIVES COMMITTEE ON HEALTH CARE SERVICES ANALYSIS BILL #: HB 2337 (PCB HCS 00-07) RELATING TO: SPONSOR(S): TIED BILL(S): Public Cord Blood Tissue Bank Committee on Health Care Services
More informationStatement of Joanne Kurtzberg, M.D.
Statement of Joanne Kurtzberg, M.D. President of the Cord Blood Association Jerome Harris Distinguished Professor of Pediatrics and Pathology Chief Scientific Officer and Medical Director, Robertson Clinical
More informationCigna Medical Coverage Policy
Cigna Medical Coverage Policy Subject Umbilical Cord Blood Banking Table of Contents Coverage Policy... 1 General Background... 1 Coding/Billing Information... 3 References... 4 Effective Date... 6/15/2014
More informationUMBILICAL CORD BLOOD HARVESTING & STORAGE
Protocol: TRP009 Effective Date: October 14, 2013 UMBILICAL CORD BLOOD HARVESTING & STORAGE Table of Contents Page COMMERCIAL, MEDICARE & MEDICAID COVERAGE RATIONALE... 1 BACKGROUND... 2 CLINICAL EVIDENCE...
More informationUMBILICAL CORD BLOOD, STEM CELL BANKING
UMBILICAL CORD BLOOD, STEM CELL BANKING Dr.Sharad Jain MD Blood Transfusion officer, & I/C Transfusion Medicine NSCB Medical College. Jabalpur.MP. Introduction: Every parent during childbirth DREAMS the
More informationUmbilical Cord Blood Stem Cells Current Status & Future Potential
Umbilical Cord Blood Stem Cells Current Status & Future Potential Natasha Ali Assistant Professor Haematology Department of Pathology & Laboratory Medicine/Oncology The Aga Khan University Email: natasha.ali@aku.edu
More informationCORD BLOOD BANKING FAQ
CORD BLOOD BANKING FAQ Cord Blood & Stem Cells Q: What is umbilical cord blood (UCB)? A: Bone marrow, peripheral blood and UCB constitute the three primary sources of stem cells. Cord blood, which, until
More informationSaving your baby s s cord blood: Is this good insurance?
Saving your baby s s cord blood: Is this good insurance? 32 th SEMINAR ON PERINATAL MEDICINE CONTROVERSIES IN PERINATAL MEDICINE: EVIDENCE FOR CURRENT PRACTICE Sante Fe, New Mexico Mervin C. Yoder, MD
More informationREGIONAL INITIATIVES. Stem Cell Research and Regenerative Medicine at King Abdullah International Medical Research Center ABSTRACT INTRODUCTION
REGIONAL INITIATIVES Stem Cell Research and Regenerative Medicine at King Abdullah International Medical Research Center Mohamed H. Abumaree, 1,2, * Ahmed S. Al Askar, 2,3 Bill Kalionis, 4 Fawaz Mohamed
More informationNarrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood
[Track 2: What Is a Transplant?] Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood can be an effective treatment for people with blood cancers such as leukemia,
More informationumbilical cord blood banking A guide for parents
umbilical cord blood banking A guide for parents 2 nd Edition 2016 This guide has been elaborated by the Council of Europe European Committee on Organ Transplantation (CD-P-TO). For more information, please
More informationBlood-Forming Stem Cell Transplants
Blood-Forming Stem Cell Transplants What are bone marrow and hematopoietic stem cells? Bone marrow is the soft, sponge-like material found inside bones. It contains immature cells known as hematopoietic
More informationCord Blood: Research Progress and Future Promise
Cord Blood: Research Progress and Future Promise By Al Staropoli, AABB Contributing Writer Sue Fister found out she had leukemia when she was 50 years old. Doctors suggested a bone marrow transplant as
More informationSTEM CELL TRANSPLANTS
UAMS Information on STEM CELL TRANSPLANTS What is a Stem Cell Transplant? A stem cell transplant is an infusion of stem cells following high-dose chemotherapy. The infused cells effectively rescue the
More informationWhat we will discuss today
Umbilical cord blood banking It s Utility? Dr. Nita Radhakrishnan Pediatric Hematology Oncology Unit, Sir Ganga Ram Hospital, New Delhi What we will discuss today What are stem cells? What are the sources
More informationcord blood saves lives...
cord blood saves lives... ...by providing a rich source of blood stem cells that can be used to treat over 80 different diseases including leukemia, lymphoma, thalassemia, Tay-Sachs and sickle cell anemia.
More informationPlacental and Umbilical Cord Blood as a Source of Stem Cells
Placental and Umbilical Cord Blood as a Source of Stem Cells Policy Number: 7.01.50 Last Review: 12/2014 Origination: 12/2001 Next Review: 12/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationTransplantation of cord blood stem cells from related or unrelated donors is considered investigational in all other situations.
MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDIX HISTORY Placental and Umbilical Cord Blood as a Source of Stem Cells
More informationCORD BLOOD TRANSPLANTATION: PAST, PRESENT AND FUTURE
CORD BLOOD TRANSPLANTATION: PAST, PRESENT AND FUTURE Dennis M. Todd, Ph.D. The New Jersey Cord Blood Bank a Division of Bergen Community Regional Blood Center Montvale, NJ Hematopoietic Stem Cell Transplantation
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): 4/1/2011 Most Recent Review Date (Revised): 3/24/2015 Effective Date: 6/1/2015 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER
More informationThe Power & Potential of Cord Blood
The Power & Potential of Cord Blood Donna Regan, MT(ASCP)SBB, Director St. Louis Cord Blood Bank & Cellular Therapy Laboratory SSM Cardinal Glennon Children s Medical Center September 18, 2013 Objectives
More informationCord Blood Banking A new horizon
Cord Blood Banking A new horizon Dr. Sushma Sharma Professor Obst. & Gyn., MIMER Medical College, Talegaon Dabhade, Pune. Abstract : Background : Umbilical cord blood is a potential vast source of primitive
More informationSEARCHING FOR A BONE MARROW DONOR
SEARCHING FOR A BONE MARROW DONOR Angela received a bone marrow transplant from an unrelated donor to treat her non-hodgkin s lymphoma. INFORMATION FOR PATIENTS AND THEIR FAMILIES For patients who need
More informationThe Impact of Maternal, Neonatal and Collections factors on the TNC count of an Umbilical Cord Blood Donation
The Impact of Maternal, Neonatal and Collections factors on the TNC count of an Umbilical Cord Blood Donation By: NHS Cord Blood Bank (Colindale Laboratory) Date: 26 th September 2014 NHS insert Cord your
More informationThe donor search: the best donor or cord blood unit
The donor search: the best donor or cord blood unit Dr Bronwen Shaw Consultant in haematopoietic cell transplantation Royal Marsden Hospital /Anthony Nolan Overview Where do we find donors/units for transplantation
More informationName of Policy: Placental/Umbilical Cord Blood as a Source of Stem Cells
Name of Policy: Placental/Umbilical Cord Blood as a Source of Stem Cells Policy #: 439 Latest Review Date: September 2014 Category: Medical Policy Grade: A Background/Definitions: As a general rule, benefits
More informationSTEM CELLS : A THERAPEUTIC REVOLUTION JACQUES KADOCH ROBERT HEMMINGS MARINELA MANDRA
STEM CELLS : A THERAPEUTIC REVOLUTION JACQUES KADOCH ROBERT HEMMINGS MARINELA MANDRA OVO CLINIC I 8000 BLVD DECARIE, MONTREAL QC H4P 2S4 I 514.798.2000 I OVOCLINIC.COM 2 a therapeutic revolution As the
More informationDo you have anything to add? If so, I d love to hear from you! Jessica Robinson Conference Manager Life Sciences @jessbiopharma
1 Who is the most influential figure in cord blood around the world? What is the biggest challenge to overcome in the use of cord blood as a source of stem cells? We asked 10 leading experts in the cord
More informationCHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION
CHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION Chapter 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION 1.1 OVERVIEW OF THE CORD BLOOD TRANSPLANTATION STUDY Bone marrow transplantation
More informationNewborn Stem Cells from Cord Blood and the Brain: Repairing Injury and Improving Function
BACKROUNDER: Newborn Stem Cells from Cord Blood and the Brain: Repairing Injury and Improving Function Introduction WITH ONGOING DEVELOPMENTS IN SCIENCE, researchers estimate that 1 in every 3 people may
More informationHow To Treat Cord Blood
Published:October2011 Thestudyreviews,analyzesandprojects theglobalmarketforcordbloodstem Cels fortheperiod2006-2015 2011alrightsreserved PRODUCT SEGMENTATION Cord blood stem cells are those adult stem
More informationCORD BLOOD BANKING PLACENTA BLOOD BANKING TISSUE BANKING WHAT YOU NEED TO KNOW THE LIFEBANKUSA GUIDEBOOK
BANKING BANKING BANKING WHAT YOU NEED TO KNOW THE LIFEBANKUSA GUIDEBOOK WORLD-CLASS LEADER IN RESEARCH AND DEVEL ORD BAN FIRST & STEM CELL TRANSPLANT IN BLO PROTECTING WHAT S MOST PRECIOUS BANKING NCE-IN-A-LIFETIME
More informationCord Blood Market Trends, circa 2014
GENReports: Market & Tech Analysis Cord Blood Market Trends, circa 2014 > Enal Razvi, Ph.D. Managing Director Select Biosciences, Inc. enal@selectbio.us Topic Introduction and Scope The focus of this GEN
More informationEUROCORD. in 49 countries and 484 transplant centres* 264 EBMT 4847 (73%) cases 220 Non-EBMT 1797 (27%) cases
! 21%! EUROCORD 6756 cord blood transplantations performed from 1988 to March 2010 in 49 countries and 484 transplant centres* 264 EBMT 4847 (73%) cases 220 Non-EBMT 1797 (27%) cases * missing center
More informationHouse Resolution No. 37
california legislature regular session House Resolution No. Introduced by Assembly Member Hill August, House Resolution No. Relative to umbilical cord blood banking. WHEREAS, Since the first umbilical
More information* CHAPTER 6. Choice of the donor according to HLA typing and stem cell source. Eliane Gluckman
* CHAPTER 6 Choice of the donor according to HLA typing and stem cell source Eliane Gluckman CHAPTER 6 Choice of the donor according to HLA typing and stem cell source 1. Introduction Allogeneic haematopoietic
More informationDirected/Related Cord Blood Collection by NHS Blood and Transplant
Directed/Related Cord Blood Collection by Jacqui Thompson Clinical Scientist Section Head of Specialist Procedures Stem Cells and Immunotherapies Department National Blood Service, NHSBT Birmingham Why
More informationANTHONY NOLAN SEARCH ALGORITHM FOR A BASIC CORD BLOOD UNIT SELECTION BY SERGIO QUEROL AND IRINA EVSEEVA FEBRUARY 2012
ANTHONY NOLAN SEARCH ALGORITHM FOR A BASIC CORD BLOOD UNIT SELECTION BY SERGIO QUEROL AND IRINA EVSEEVA FEBRUARY 2012 PAGE 1 OF 7 PRINCIPLES FOR A NEW ALGORITHM Once cord blood transplantation (CBT) is
More informationEquine Stem Cells. Sources, Processing, Expansion, Storage and Shipping
Equine Stem Cells Sources, Processing, Expansion, Storage and Shipping Sean Owens, DVM, Diplomate ACVP Medical Director, UC Davis Veterinary Regenerative Medicine Laboratory What is a Stem Cell and What
More informationOne-Unit versus Two-Unit Cord-Blood Transplantation for Hematologic Cancers
The new england journal of medicine Original Article One-Unit versus Two-Unit Cord-Blood Transplantation for Hematologic Cancers John E. Wagner, Jr., M.D., Mary Eapen, M.B., B.S., Shelly Carter, D.Sc.,
More informationReview. Cord blood as an alternative source of haemopoietic stem cells. J. Hows, A. Nicol, P. Denning-Kendall, C. Donaldson, M. Nieda & B.
Annals of Oncology 7 (Suppi 2): 47-51, 1996. O 1996 Kluwer Academic Publishers. Printed in the Netherlands. Review Cord blood as an alternative source of haemopoietic stem cells J. Hows, A. Nicol, P. Denning-Kendall,
More informationhematopoietic stem cells from cord blood: - costless but too expensive? Dr. Vincent Kindler Geneva Cord Blood Bank HUG vincent.kindler@hcuge.
hematopoietic stem cells from cord blood: - costless but too expensive? Dr. Vincent Kindler Geneva Cord Blood Bank HUG vincent.kindler@hcuge.ch Spring water: Manufactured by nature COSTLESS Cord Blood:
More informationSepax. your child s cord blood is in safe hands. World leader in adult stem cell processing
Sepax your child s cord blood is in safe hands World leader in adult stem cell processing Biosafe Experience Credibility Innovation Dear Customer, Innovation in cell processing is our credo and this is
More informationCancer: A Comparison of Cord Blood and Bone-marrow transplantation
UMBILICAL-CORD BLOOD TRANSPLANTATION FOR THE TREATMENT OF CANCER Juliet N. Barker* and John E. Wagner Haematopoietic stem-cell transplantation is used to treat many haematological cancers, but is limited
More informationINFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002
INFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002 COVERAGE: SPECIAL COMMENT ON POLICY REVIEW: Due to the complexity of the Peripheral and Bone Marrow Stem Cell Transplantation
More informationIn a number of genetic, hematologic, and oncologic
AMERICAN ACADEMY OF PEDIATRICS Cord Blood Banking for Potential Future Transplantation: Subject Review ABSTRACT. In recent years, umbilical cord blood, which contains a large number of hematopoietic stem
More informationPatients Knowledge of Umbilical Cord Blood Banking DO NOT DUPLICATE
The Journal of Reproductive Medicine Patients Knowledge of Umbilical Cord Blood Banking Jordan H. Perlow, M.D. OBJECTIVE: To determine patients knowledge of umbilical cord blood banking (UCBB). METHODS:
More informationThe Leading Cell Bank www.stemology.co.uk. Protect Your Family s Future. Stem Cell Banking. Umbilical Cord. Only for Expecting Parents
Protect Your Family s Future The Leading Cell Bank www.stemology.co.uk Stem Cell Banking Umbilical Cord Only for Expecting Parents Introduction to Stemology Imagine you could replace any cells in your
More informationPros and Cons of Stem Cell Sources and their availability in Africa. Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa
Pros and Cons of Stem Cell Sources and their availability in Africa Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa Introduction The ability to perform a haematopoietic stem
More informationTherapeutic Potential of Cells Derived from Gestational Tissues: A coming of age. Dr Roisin Deane Cell Care Australia Pty Ltd
Therapeutic Potential of Cells Derived from Gestational Tissues: A coming of age Dr Roisin Deane Cell Care Australia Pty Ltd What are Gestational Stem Cells? Stem cells isolated from the gestational tissues
More informationDouble cord blood transplantation
DCTH - 2 2013-113-121 REVIEW Double cord blood transplantation R. Angarano, I. Donnini, B. Bartolozzi, A. Bosi Ematologia, Azienda Ospedaliera Universitaria Careggi, Università di Firenze, Italy SUMMARY
More informationEnumeration and Viability of Nucleated Cells from Bone Marrow, Cord Blood, and Mobilized Peripheral Blood
Application Note Primary Cell Analysis Enumeration and Viability of Nucleated Cells from Bone Marrow, Cord Blood, and Mobilized Peripheral Blood Cell Viability Introduction: Bone Marrow, Cord Blood, Stem
More information